M-protein Decrement and Survival in Multiple Myeloma
Author Information
Author(s): M. Palmer, A. Belch, J. Hanson, L. Brox
Primary Institution: University of Alberta
Hypothesis
Is there a significant correlation between percentage M-protein decrement and survival in multiple myeloma patients?
Conclusion
The study concludes that M-protein decrement is not a reliable indicator of treatment efficacy or survival in multiple myeloma patients.
Supporting Evidence
- The median survival for the patients was 30 months.
- 77% of the evaluable patients were deceased at the time of analysis.
- Only 15% of the variance in survival could be attributed to M-protein decrement.
Takeaway
This study found that how much M-protein decreases in multiple myeloma patients doesn't really help us know how long they will live.
Methodology
Retrospective analysis of 134 multiple myeloma patients, assessing the correlation between M-protein decrement and survival using multivariate analysis.
Limitations
The prognostic power of the significant factors was low, indicating minimal predictive value.
Participant Demographics
Patients included 12% stage I, 38% stage II, and 50% stage III disease; 80% had IgG myeloma and 20% had IgA myeloma.
Statistical Information
P-Value
0.069
Statistical Significance
p=0.069
Want to read the original?
Access the complete publication on the publisher's website